ABOS
NASDAQ · Biotechnology
Acumen Pharmaceuticals Inc
$2.55
+0.04 (+1.59%)
Open$2.50
Previous Close$2.51
Day High$2.55
Day Low$2.39
52W High$3.60
52W Low$1.19
Volume—
Avg Volume344.3K
Market Cap176.24M
P/E Ratio—
EPS$-1.86
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+771.4% upside
Current
$2.55
$2.55
Target
$22.22
$22.22
$18.81
$22.22 avg
$35.10
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 32.13M | 32.40M | 26.28M |
| Net Income | 3.79M | 3.97M | 2.79M |
| Profit Margin | 11.8% | 12.2% | 10.6% |
| EBITDA | 5.50M | 6.39M | 4.32M |
| Free Cash Flow | 1.86M | 2.43M | 2.61M |
| Rev Growth | +20.9% | +8.5% | +2.1% |
| Debt/Equity | 0.36 | 0.35 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |